Allarity Therapeutics, Inc. · NASDAQ:ALLR
Allarity Therapeutics — Investor Presentation (May 2025)
24 slides from Allarity Therapeutics's investor presentation, May 2025
Slide 1: Allarity: Unique PARP/Tankyrase inhibitor
Allarity: • Unique PARP/Tankyrase inhibitor • DRP® : Gene Expression Based Biomarker For Predicting Response To Cancer Therapy Thomas Jensen, CEO May 2025 NASDAQ: ALLR Nasdaq: ALLR Copyright © 2023 Allarity Therapeutics. All rights reserved.
Slide 2: Legal Statement
Legal Statement This presentation is provided for informational purposes only and is subject to change. The information contained herein does not purport to be all-inclusive. The data contained herein is derived from various internal and external sources, and may rely upon assumptions, stated or oth
Slide 3: Our DRP Companion Diagnostics Platform
Our DRP® Companion Diagnostics Platform
Slide 4: The DRP Platform Addresses the Complexity of Cancer
The DRP® Platform Addresses the Complexity of Cancer Cancer is Very Complex The Tumor Tells us What is Important “Systems biology” is used to analyze all genes (~25,000) Input is generated by taking drug testing data from cancer cell expressed in a cancer cell/tumor, without bias towards lines. Our
Slide 5: DRP CDx: Predicting a Cancer Patient's Drug Response
DRP® CDx: Predicting a Cancer Patient’s Drug Response Step 1 Step 2 Step 3 Patients’ biopsy samples Compare patients’ tumor gene Identify patients with high DRP® expression to DRP® signature score for a given drug MODERATE STRONG STRONG WEAK WEAK PATIENTS’ TUMORS PATIENTS’ TUMORS DRP + Allarity Ther
Slide 6: LiPlaCis: Prospective enrollment based on DRP identifies patients with greatest clinical benefit
LiPlaCis: Prospective enrollment based on DRP identifies patients with greatest clinical benefit Results of LiPlaCis Phase II Trial* Results of LiPlaCis Phase II Trial 100 Allarity’s LiPlaCis DRP ® was used to screen patients for inclusion into trial based on 90 diagnostic biopsy. DRP predicted LiPl
Slide 7: Personal Response Prediction: which drug will work best for a tumor?
Personal Response Prediction: which drug will work best for a tumor? High Risk Myeloma patients are generally difficult to treat. There is limited guidance on which treatment will work. 67 High risk myeloma patients. DRP predictions for 14 drugs green=predicted sensitive red=predicted resistant Alla
Slide 8: Publications of Clinical/Method Validation for Drug-Specific DRPs
Publications of Clinical/Method Validation for Drug-Specific DRP®’s 1. Chen J, et al. A 71-gene signature of TRAIL sensitivity in cancer cells. (October 25, 2011); Mol Cancer Ther, 10.1158/1535-7163. 2. Wang W, et al. Independent validation of a model using cell line chemosensitivity to predict resp
Slide 9: Revitalizing Former Big Pharma Therapeutics with Our DRP CDx
Revitalizing Former Big Pharma Therapeutics with Our DRP® CDx Classical Drug Development Allarity Approach Treat all of the patients Treat only patients sensitive to therapy Companion Low Average Diagnostics High Average Patient Benefit Patient Benefit PHASE 1/1b PHASE 2 PHASE 3 INDICATION RIGHTS Le
Slide 10: Ongoing Phase 2 Prospective trial: Stenoparib
Ongoing Phase 2 Prospective trial: Stenoparib
Slide 11: Stenoparib: A Unique Dual PARP and Tankyrase Inhibitor
Stenoparib: A Unique Dual PARP and Tankyrase Inhibitor Ongoing Phase 2 Monotherapy Study in 3rd Line Ovarian Cancer (OC) All patients screened with Stenoparib DRP to identify patients for inclusion • First-in-class small molecule targeted inhibitor of DNA damage repair Stenoparib (E7449) targets Wnt
Slide 12: Durable Clinical Benefit from Stenoparib Monotherapy
Ongoing Phase 2 study in 3L+ Ovarian Cancer Patients: Durable Clinical Benefit from Stenoparib Monotherapy BID 0 US02−002 0 US03−009 0 US03−003 0 US03−012 CRs are unprecedented 0 US03−002 in the PARPi re-treated 1 US02−006 patient population CR 1 US03−013 PR 1 US02−008 SD Benefit independent of 1 US
Slide 13: Patient 1: Confirmed Complete Response on Treatment
Patient 1: Confirmed Complete Response > 30 weeks on Treatment Platinum Resistant, prior PARPi, prior Checkpoint inhibitor Tumor BRCA2 mutation, HRD positive 200 Tumor SLD CA125 Treatment History Tumor SLD and CA125 relative to baseline (=100) • 2015 total hysterectomy w bilateral salpingo-oophorect
Slide 14: Patient 2: Stable Disease, on Treatment More Than 19 Months
Patient 2: Stable Disease, on Treatment More Than 19 months Platinum Resistant, PARPi prior treatment, Post Elahere, Post Bevacizumab Germline BRCA1 mutation, HRD positive 250 Tumor SLD and CA125 relative to baseline (=100) Treatment History 200 • 2007 debulking surgery plus adjuvant chemotherapy (c
Slide 15: Patient 3: Stable Disease, on Treatment More than 19 Months
Patient 3: Stable Disease, on Treatment More than 19 months Platinum Resistant, PARPi naïve, Germline BRCA wild type 200 Tumor SLD CA125 Treatment History Tumor SLD and CA125 relative to baseline (=100) • 2020 total hysterectomy and rectosigmoid tumor resection 150 • 2021 carboplatin plus gemcitabin
Slide 16: Stenoparib Shows Low Myelotoxicity
Stenoparib Shows Low Myelotoxicity Potential Best-in-Class Safety Profile & Ability to Combine with Other Drugs Stenoparib QD+BID (N=42)1 Approved PARPi ex. Niraparib QD (N=463)2 Grade 1-4 Grade 3-4 Grade 1-4 Grade 3-4 Neutropenia 2% 0% Neutropenia 20% 13% Anemia 21% 7% Anemia 51% 27% Thrombocytopen
Slide 17: Stenoparib BID compares favorably to PARP1 selective Saruparib
Stenoparib BID compares favorably to the PARP 1 selective Saruparib currently under development by AstraZeneca Potential Best-in-Class Safety Profile & Ability to Combine with Other Drugs Stenoparib BID (N=14)1 PARP1 selective Saruparib QD (N=141)2 Grade 1-4 Grade 3-4 Grade 1-4 Grade 3-4 Neutropenia
Slide 18: New Protocol for Phase 2 Trial in Ovarian Cancer
New Protocol for Phase 2 Trial in Ovarian Cancer: Stenoparib Monotherapy in Platinum Resistant or Ineligible Ovarian Cancer Objective: Solidify Dose for Pivotal Trial, Establish Cut-point for DRP Pre-selection in Pivotal Trial Patients with Platinum resistant or Platinum ineligible disease ➢ No more
Slide 19: VA sponsored Phase 2: Stenoparib + TMZ in recurrent SCLC
VA sponsored Phase 2: Stenoparib + TMZ in recurrent SCLC ➢ Niraparib was the original PARPi used in design but is being replaced by Stenoparib ➢ Biomarkers are blood-based methylation marks ➢ Safety lead in ➢ 200mg steno + TMZ ➢ 200mg steno BID + TMZ ➢ 200 + 400mg Steno + TMZ Fully funded, need only
Slide 20: Allarity Therapeutics Financial Highlights
Allarity Therapeutics Financial Highlights Market Cap: ~$15 million • Runway into 2027 with first substantive clinical data expected mid 2026. • Streamlined cap table is primarily all common stock. Allarity Therapeutics 20
Slide 21: Stenoparib: A Unique, Oral Dual PARP and Tankyrase Inhibitor
Stenoparib: A Unique, Oral Dual PARP and Tankyrase Inhibitor Best-in-class, orally administered small molecule inhibitor of PARP and Tankyrase ➢ PARP inhibition disables DNA Repair, leading to selective cancer cell death ➢ Tankyrase Inhibition blocks key cell survival pathways activated in cancer ce
Slide 22: Stenoparib MOA and Clinical Data Suggest Numerous Clinical Opportunities
Stenoparib MOA and Clinical Data Suggest Numerous Clinical Opportunities and Value Driving Catalysts Ovarian Cancer – opportunities across the patient landscape • Platinum sensitive, resistant and refractory disease • BRCA wt and mut patients • PARPi retreatment • Maintenance and active disease Othe
Slide 23: Allarity's DRP can effectively ringfence patients most likely to benefit
Allarity’s DRP can effectively ringfence patients most likely to benefit from anti-cancer therapies. • DRP has been successful in selecting patients achieving benefit in a number of indications with a number of drugs • DRP has been prospectively used in a trial of LiPlaCis where it was able to enric
Slide 24: Thomas Jensen CEO
Thomas Jensen CEO tjensen@allarity.com allarity.com NASDAQ: ALLR
Allarity Therapeutics — Investor Presentation (May 2025) on 6ix